Ablynx NV Aktie
WKN DE: A0M7H2 / ISIN: BE0003877942
18.02.2016 07:00:10
|
ABLYNX WILL ANNOUNCE ITS 2015 FULL YEAR RESULTS WITH WEBCAST ON 25 FEBRUARY 2016
GHENT, Belgium, 18 February 2016 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will announce its full year results for 2015 on Thursday 25 February 2016 at 7.00 am CET.
The Ablynx management team will host a conference call and webcast during which the full year results for 2015 will be presented, followed by a Q&A session. This event will be held on Thursday 25 February 2016 at 4.00 pm CET/10.00 am EST.
The conference call will be webcast live and may be accessed by clicking here. If you would like to participate in the Q&A session, please dial +32(0)2 404 06 62 and use confirmation code 4640794. Shortly after the call, a replay of the webcast and copy of the presentation will be available on the Ablynx website under http://www.ablynx.com/news/events-presentations/.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has approximately 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media relations
Instinctif Partners:
Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e: ablynx@instinctif.com
Belgium/Dutch and French language
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e: ablynx@instinctif.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Ablynx NVmehr Nachrichten
Keine Nachrichten verfügbar. |